Individualizing aspirin therapy for prevention of cardiovascular events
- PMID: 9851483
- DOI: 10.1001/jama.280.22.1949
Individualizing aspirin therapy for prevention of cardiovascular events
Comment in
-
Aspirin and risk of hemorrhagic stroke.JAMA. 1999 Aug 25;282(8):731-2; author reply 732-3. doi: 10.1001/jama.282.8.731. JAMA. 1999. PMID: 10463702 No abstract available.
Comment on
-
Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.JAMA. 1998 Dec 9;280(22):1930-5. doi: 10.1001/jama.280.22.1930. JAMA. 1998. PMID: 9851479
Similar articles
-
Aspirin: real benefits, but real risks, too.Harv Heart Lett. 1999 May;9(9):1-3. Harv Heart Lett. 1999. PMID: 10200029 Review. No abstract available.
-
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.Am Heart J. 2011 Jul;162(1):115-24.e2. doi: 10.1016/j.ahj.2011.04.006. Am Heart J. 2011. PMID: 21742097 Review.
-
Aspirin and risk of hemorrhagic stroke.JAMA. 1999 Aug 25;282(8):731-2; author reply 732-3. doi: 10.1001/jama.282.8.731. JAMA. 1999. PMID: 10463702 No abstract available.
-
Aspirin for primary prevention of cardiovascular disease in Japan.Intern Med. 2007;46(15):1281. doi: 10.2169/internalmedicine.46.0212. Epub 2007 Aug 2. Intern Med. 2007. PMID: 17675791 No abstract available.
-
Aspirin in the primary prevention of cardiovascular disease.Maturitas. 2011 Jan;68(1):3-4. doi: 10.1016/j.maturitas.2010.09.011. Epub 2010 Dec 15. Maturitas. 2011. PMID: 21111550 No abstract available.
Cited by
-
In Silico Clinical Trials: Is It Possible?Methods Mol Biol. 2024;2716:51-99. doi: 10.1007/978-1-0716-3449-3_4. Methods Mol Biol. 2024. PMID: 37702936
-
Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions.Nat Commun. 2022 Apr 13;13(1):1980. doi: 10.1038/s41467-022-29534-8. Nat Commun. 2022. PMID: 35418135 Free PMC article.
-
Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation.Eur J Clin Pharmacol. 2004 Nov;60(9):609-16. doi: 10.1007/s00228-004-0816-2. Epub 2004 Sep 16. Eur J Clin Pharmacol. 2004. PMID: 15378222
-
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.BMJ. 2000 Jul 1;321(7252):13-7. doi: 10.1136/bmj.321.7252.13. BMJ. 2000. PMID: 10875825 Free PMC article. Clinical Trial.
-
Effect model law: an approach for the implementation of personalized medicine.J Pers Med. 2013 Aug 15;3(3):177-90. doi: 10.3390/jpm3030177. J Pers Med. 2013. PMID: 25562651 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical